Article(id=1329913768684925705, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913746920681993, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2018.10.012, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1529856000000, receivedDateStr=2018-06-25, revisedDate=1535904000000, revisedDateStr=2018-09-03, acceptedDate=null, acceptedDateStr=null, onlineDate=1795005751056, onlineDateStr=2026-11-18, pubDate=1539100800000, pubDateStr=2018-10-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795005751056, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795005751056, creator=13701087609, updateTime=1795005751056, updator=13701087609, issue=Issue{id=1329913746920681993, tenantId=1146029695717560320, journalId=1319690329412173987, year='2018', volume='39', issue='10', pageStart='649', pageEnd='720', issueExtLink='null', onlineDate='null', pubDate='1539100800000', pubDateStr='2018-10-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795005745868, creator='13701087609', updateTime=1795056465582, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330126481231033225, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913746920681993, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330126481231033226, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329913746920681993, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=705, endPage=711, ext={EN=ArticleExt(id=1329913768873669387, articleId=1329913768684925705, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress in targeted drug therapy for pulmonary hypertension associated with left heart disease, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Pulmonary hypertension (PH) is a common clinical disease and can be caused by various heart and lung diseases. The PH caused by left heart disease (PH-LHD) is the most common, which can induce the dyspnea, fatigue, reduced exercise tolerance and even heart failure. However, the PH-LHD may have high rate of disability and mortality, and seriously affect patients' life quality. With extensive study of PH-LHD pathophysiological mechanism, the targeted drugs have been developed, which causes more and more attention. This review summarizes PH-LHD related targeted therapeutic drugs for clinical reference.

, authors=Gang ZHENG, authorsList=Gang ZHENG, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329913769146299148, articleId=1329913768684925705, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=左心疾病相关肺动脉高压靶向药物治疗研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

肺动脉高压(PH)是临床常见疾病,可由多种心、肺疾病引起,其中以由左心疾病所导致的肺动脉高压(PH-LHD)为最多见。PH可导致患者出现呼吸困难、乏力、运动耐量降低甚至发生心力衰竭,严重影响患者的生活质量,且其具有较高的致残率及死亡率。随着近年对PH-LHD病理生理机制研究的不断深入,靶向治疗药物开始引起人们关注。本文主要综述PH-LHD相关的靶向治疗药物,以供临床参考。

, authors=郑刚, authorsList=郑刚, authorCompany=null, correspAuthors=null, authorNote=

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=UwvQKGQKUDsnZ5bPBOgBlg==, magXml=d/aEkiwd0RV7A6JmKU8YwA==, pdfUrl=null, pdf=BOseTENrRaIDmut80SpoMQ==, pdfFileSize=938344, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=hC8Qqc0tSQ8wxEOeVgN9bQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329913769448289042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913769519592211, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, authorId=1329913769448289042, language=EN, stringName=Gang ZHENG, firstName=Gang, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913769590895380, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, authorId=1329913769448289042, language=CN, stringName=郑刚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=天津市第三中心医院分院心内科,天津 300250, bio={"content":"

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

"}, bioImg=null, bioContent=

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913769364402957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, xref=null, ext=[AuthorCompanyExt(id=1329913769372791566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China), AuthorCompanyExt(id=1329913769381180175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津市第三中心医院分院心内科,天津 300250)])])], keywords=[Keyword(id=1329913769691558677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=EN, orderNo=1, keyword=pulmonary hypertension (PH)), Keyword(id=1329913769754473238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=EN, orderNo=2, keyword=targeted drug), Keyword(id=1329913769813193495, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=EN, orderNo=3, keyword=treatment), Keyword(id=1329913769880302360, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=CN, orderNo=1, keyword=肺动脉高压(PH)), Keyword(id=1329913769934828313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=CN, orderNo=2, keyword=靶向药物), Keyword(id=1329913769997742874, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, language=CN, orderNo=3, keyword=治疗)], refs=[Reference(id=1329913770077434651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Desai A, Desouza SA. Treatment of pulmonary hypertension with left heart disease: a concise review[J]. Vasc Health Risk Manag, 2017, 13: 415-420., articleTitle=null, refAbstract=null), Reference(id=1329913770148737820, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Chung K, Strange G, Codde J, et al. Left heart disease and pulmonary hypertension: are we seeing the full picture?[J]. Heart Lung Circ, 2018, 27(3): 301-309., articleTitle=null, refAbstract=null), Reference(id=1329913770211652381, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS)[J]. Eur Heart J, 2016, 37(1): 67-119., articleTitle=null, refAbstract=null), Reference(id=1329913770270372638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart J, 2016, 37(12): 942-954., articleTitle=null, refAbstract=null), Reference(id=1329913770337481503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Naeije R, Gerges M, Vachiery JL, et al. Hemodynamic phenotyping of pulmonary hypertension in left heart failure[J]. Circ Heart Fail, 2017, 10(9): e004082-e004082., articleTitle=null, refAbstract=null), Reference(id=1329913770404590368, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension[J]. J Am Coll Cardiol, 2017, 69(2): 236-243., articleTitle=null, refAbstract=null), Reference(id=1329913770459116321, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Adusumalli S, Mazurek JA. Pulmonary hypertension due to left ventricular cardiomyopathy: is it the result or cause of disease progression?[J]. Curr Heart Fail Rep, 2017, 14(6): 507-513., articleTitle=null, refAbstract=null), Reference(id=1329913770513642274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Meng Q, Lai YC, Kelly NJ, et al. Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction[J]. Am J Respir Cell Mol Biol, 2017, 56(4): 497-505., articleTitle=null, refAbstract=null), Reference(id=1329913770584945444, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Makeeva LM, Emelina EI, Gendlin GE, et al. Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report[J]. Kardiologiia, 2017, 57(S4): 53-60., articleTitle=null, refAbstract=null), Reference(id=1329913770652054309, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Dumas SJ, Bru-Mercier G, Courboulin A, et al. NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension[J]. Circulation, 2018, 137(22): 2371-2389., articleTitle=null, refAbstract=null), Reference(id=1329913770731746086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction[J]. Circulation, 2018, 137(17): 1796-1810., articleTitle=null, refAbstract=null), Reference(id=1329913770807243559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Low A, George S, Howard L, et al. Lung function, inflammation, and endothelin-1 in congenital heart disease-associated pulmonary arterial hypertension[J]. J Am Heart Assoc, 2018, 7(4): e007249-e007249., articleTitle=null, refAbstract=null), Reference(id=1329913770870158120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. Circulation, 2016, 133(8): 717-731., articleTitle=null, refAbstract=null), Reference(id=1329913770954044201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Ghio S, Crimi G, Temporelli PL, et al. Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension[J]. Eur J Heart Fail, 2017, 20(7): 725-734., articleTitle=null, refAbstract=null), Reference(id=1329913771021153066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Simon MA, Vanderpool RR, Nouraie M, et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. JCI Insight, 2016, 1(18): e89620-e89620., articleTitle=null, refAbstract=null), Reference(id=1329913771075679019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study[J]. Am J Cardiovasc Drugs, 2018, 18(1): 37-47., articleTitle=null, refAbstract=null), Reference(id=1329913771142787884, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Preston IR, Channick RN, Chin K, et al. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: insights from the prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (GRIPHON) study[J]. J Heart Lung Transplant, 2018, 37(3): 401-408., articleTitle=null, refAbstract=null), Reference(id=1329913771239256877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction[J]. Eur Respir J, 2018, 51(2): 1701886-1701886., articleTitle=null, refAbstract=null), Reference(id=1329913771310560046, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Mehta S, Sastry BK, Souza R, et al. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial[J]. Chest, 2017, 151(1): 106-118., articleTitle=null, refAbstract=null), Reference(id=1329913771373474607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial)[J]. Heart Lung Circ, 2017, 26(5): 433-441., articleTitle=null, refAbstract=null), Reference(id=1329913771457360688, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial[J]. J Am Med Assoc, 2013, 309(12): 1268-1277., articleTitle=null, refAbstract=null), Reference(id=1329913771537052465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial[J]. Eur Heart J, 2015, 36(38): 2565-2573., articleTitle=null, refAbstract=null), Reference(id=1329913771599967026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Gómez Sánchez MÁ, Barrios Garrido-Lestache E. Selection of the best of 2016 in the treatment of pulmonary hypertension[J]. Rev Esp Cardiol, 2017, 70(4): 297-306., articleTitle=null, refAbstract=null), Reference(id=1329913771662881587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Bermejo J, Yotti R, García-Orta R, et al. SIOVAC investigators. sildenafil for improving outcomes in patients with corrected valvular heart diseaseand persistent pulmonary hypertension: multicenter, double-blind, randomizedclinical trial[J]. Eur Heart J, 2018, 39(15): 1255-1264., articleTitle=null, refAbstract=null), Reference(id=1329913771729990452, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu LC, Hummel YM, van der Meer P, et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension[J]. Eur J Heart Fail, 2017, 19(1): 116-125., articleTitle=null, refAbstract=null), Reference(id=1329913771906151221, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase Ⅱ b double-blind, randomized, placebo-controlled, doseranging hemodynamic study[J]. Circulation, 2013, 128(5): 502-511., articleTitle=null, refAbstract=null), Reference(id=1329913772002620214, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study[J]. Chest, 2014, 146(5): 1274-1285., articleTitle=null, refAbstract=null), Reference(id=1329913772082311991, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Mascherbauer J, Grünig E, Halank M, et al. Evaluation of the pharmaco DYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: study protocol for a randomized controlled trial[J]. Wien Klin Wochenschr, 2016, 128(23-24): 882-889., articleTitle=null, refAbstract=null), Reference(id=1329913772162003768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther, 2016, 44(11-12): 1183-1198., articleTitle=null, refAbstract=null), Reference(id=1329913772275249977, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Egom EE, Feridooni T, Pharithi RB, et al. A natriuretic peptides clearance receptor's agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: new hope for patients with pulmonary hypertension due to left ventricular heart failure[J]. Biomed Pharmacother, 2017, 93: 1144-1150., articleTitle=null, refAbstract=null), Reference(id=1329913772333970234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Jiang R, Zhao QH, Wu WH, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension[J]. Clin Respir J, 2018, 12(4): 1518-1525., articleTitle=null, refAbstract=null), Reference(id=1329913772405273403, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang Q, Guo YZ, Zhang YT, et al. The effects and mechanism of atorvastatin on pulmonary hypertension due to left heart disease[J]. PLoS One, 2016, 11(7): e0157171-e0157171., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329913769364402957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, xref=null, ext=[AuthorCompanyExt(id=1329913769372791566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China), AuthorCompanyExt(id=1329913769381180175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津市第三中心医院分院心内科,天津 300250)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.10.012, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.10.012, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2018.10.012, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2018.10.012, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1539100800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
左心疾病相关肺动脉高压靶向药物治疗研究进展
郑刚
世界临床药物 | 综述评论 2018,39(10): 705-711
收起
收藏切换
世界临床药物 |综述评论 2018 , 39 (10) : 705 -711
左心疾病相关肺动脉高压靶向药物治疗研究进展
全屏
[Author(id=1329913769448289042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329913769519592211, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, authorId=1329913769448289042, language=EN, stringName=Gang ZHENG, firstName=Gang, middleName=null, lastName=ZHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329913769590895380, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, authorId=1329913769448289042, language=CN, stringName=郑刚, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=天津市第三中心医院分院心内科,天津 300250, bio={"content":"

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

"}, bioImg=null, bioContent=

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329913769364402957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, xref=null, ext=[AuthorCompanyExt(id=1329913769372791566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China), AuthorCompanyExt(id=1329913769381180175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329913768684925705, companyId=1329913769364402957, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津市第三中心医院分院心内科,天津 300250)])])]
郑刚
作者信息
  • 天津市第三中心医院分院心内科,天津 300250
作者简介:

郑刚,科主任,主任医师,教授,研究方向:心力衰竭及高血压的诊断和治疗。

Progress in targeted drug therapy for pulmonary hypertension associated with left heart disease
Gang ZHENG
Affiliations
  • Department of Cardiology, Tianjin Third Center Hospital Branch, Tianjin 300250, China
出版时间: 2018-10-10 doi: 10.13683/j.wph.2018.10.012
文章导航
收藏切换

肺动脉高压(PH)是临床常见疾病,可由多种心、肺疾病引起,其中以由左心疾病所导致的肺动脉高压(PH-LHD)为最多见。PH可导致患者出现呼吸困难、乏力、运动耐量降低甚至发生心力衰竭,严重影响患者的生活质量,且其具有较高的致残率及死亡率。随着近年对PH-LHD病理生理机制研究的不断深入,靶向治疗药物开始引起人们关注。本文主要综述PH-LHD相关的靶向治疗药物,以供临床参考。

肺动脉高压(PH)  /  靶向药物  /  治疗

Pulmonary hypertension (PH) is a common clinical disease and can be caused by various heart and lung diseases. The PH caused by left heart disease (PH-LHD) is the most common, which can induce the dyspnea, fatigue, reduced exercise tolerance and even heart failure. However, the PH-LHD may have high rate of disability and mortality, and seriously affect patients' life quality. With extensive study of PH-LHD pathophysiological mechanism, the targeted drugs have been developed, which causes more and more attention. This review summarizes PH-LHD related targeted therapeutic drugs for clinical reference.

pulmonary hypertension (PH)  /  targeted drug  /  treatment
郑刚. 左心疾病相关肺动脉高压靶向药物治疗研究进展. 世界临床药物, 2018 , 39 (10) : 705 -711 . DOI: 10.13683/j.wph.2018.10.012
Gang ZHENG. Progress in targeted drug therapy for pulmonary hypertension associated with left heart disease[J]. World Clinical Drug, 2018 , 39 (10) : 705 -711 . DOI: 10.13683/j.wph.2018.10.012

参考文献 引证文献
排序方式:
[1]
Desai A, Desouza SA. Treatment of pulmonary hypertension with left heart disease: a concise review[J]. Vasc Health Risk Manag, 2017, 13: 415-420.
[2]
Chung K, Strange G, Codde J, et al. Left heart disease and pulmonary hypertension: are we seeing the full picture?[J]. Heart Lung Circ, 2018, 27(3): 301-309.
[3]
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS)[J]. Eur Heart J, 2016, 37(1): 67-119.
[4]
Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart J, 2016, 37(12): 942-954.
[5]
Naeije R, Gerges M, Vachiery JL, et al. Hemodynamic phenotyping of pulmonary hypertension in left heart failure[J]. Circ Heart Fail, 2017, 10(9): e004082-e004082.
[6]
Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension[J]. J Am Coll Cardiol, 2017, 69(2): 236-243.
[7]
Adusumalli S, Mazurek JA. Pulmonary hypertension due to left ventricular cardiomyopathy: is it the result or cause of disease progression?[J]. Curr Heart Fail Rep, 2017, 14(6): 507-513.
[8]
Meng Q, Lai YC, Kelly NJ, et al. Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction[J]. Am J Respir Cell Mol Biol, 2017, 56(4): 497-505.
[9]
Makeeva LM, Emelina EI, Gendlin GE, et al. Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report[J]. Kardiologiia, 2017, 57(S4): 53-60.
[10]
Dumas SJ, Bru-Mercier G, Courboulin A, et al. NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension[J]. Circulation, 2018, 137(22): 2371-2389.
[11]
Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction[J]. Circulation, 2018, 137(17): 1796-1810.
[12]
Low A, George S, Howard L, et al. Lung function, inflammation, and endothelin-1 in congenital heart disease-associated pulmonary arterial hypertension[J]. J Am Heart Assoc, 2018, 7(4): e007249-e007249.
[13]
Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. Circulation, 2016, 133(8): 717-731.
[14]
Ghio S, Crimi G, Temporelli PL, et al. Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension[J]. Eur J Heart Fail, 2017, 20(7): 725-734.
[15]
Simon MA, Vanderpool RR, Nouraie M, et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. JCI Insight, 2016, 1(18): e89620-e89620.
[16]
Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study[J]. Am J Cardiovasc Drugs, 2018, 18(1): 37-47.
[17]
Preston IR, Channick RN, Chin K, et al. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: insights from the prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (GRIPHON) study[J]. J Heart Lung Transplant, 2018, 37(3): 401-408.
[18]
Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction[J]. Eur Respir J, 2018, 51(2): 1701886-1701886.
[19]
Mehta S, Sastry BK, Souza R, et al. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial[J]. Chest, 2017, 151(1): 106-118.
[20]
Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial)[J]. Heart Lung Circ, 2017, 26(5): 433-441.
[21]
Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial[J]. J Am Med Assoc, 2013, 309(12): 1268-1277.
[22]
Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial[J]. Eur Heart J, 2015, 36(38): 2565-2573.
[23]
Gómez Sánchez MÁ, Barrios Garrido-Lestache E. Selection of the best of 2016 in the treatment of pulmonary hypertension[J]. Rev Esp Cardiol, 2017, 70(4): 297-306.
[24]
Bermejo J, Yotti R, García-Orta R, et al. SIOVAC investigators. sildenafil for improving outcomes in patients with corrected valvular heart diseaseand persistent pulmonary hypertension: multicenter, double-blind, randomizedclinical trial[J]. Eur Heart J, 2018, 39(15): 1255-1264.
[25]
Liu LC, Hummel YM, van der Meer P, et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension[J]. Eur J Heart Fail, 2017, 19(1): 116-125.
[26]
Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase Ⅱ b double-blind, randomized, placebo-controlled, doseranging hemodynamic study[J]. Circulation, 2013, 128(5): 502-511.
[27]
Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study[J]. Chest, 2014, 146(5): 1274-1285.
[28]
Mascherbauer J, Grünig E, Halank M, et al. Evaluation of the pharmaco DYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: study protocol for a randomized controlled trial[J]. Wien Klin Wochenschr, 2016, 128(23-24): 882-889.
[29]
Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther, 2016, 44(11-12): 1183-1198.
[30]
Egom EE, Feridooni T, Pharithi RB, et al. A natriuretic peptides clearance receptor's agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: new hope for patients with pulmonary hypertension due to left ventricular heart failure[J]. Biomed Pharmacother, 2017, 93: 1144-1150.
[31]
Jiang R, Zhao QH, Wu WH, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension[J]. Clin Respir J, 2018, 12(4): 1518-1525.
[32]
Wang Q, Guo YZ, Zhang YT, et al. The effects and mechanism of atorvastatin on pulmonary hypertension due to left heart disease[J]. PLoS One, 2016, 11(7): e0157171-e0157171.
2018年第39卷第10期
14
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2018.10.012
  • 接收时间:2018-06-25
  • 首发时间:2026-11-18
  • 出版时间:2018-10-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2018-06-25
  • 修回日期:2018-09-03
基金
作者信息
    天津市第三中心医院分院心内科,天津 300250
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2018.10.012
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏